Lipid-based Nanoparticles: Strategy for Targeted Cancer Therapy

Abstract

Lipid-based Nanoparticles (LBNPs) have emerged as a transformative approach in cancer treatment, offering innovative drug delivery solutions that enhance therapeutic efficacy while minimizing adverse effects. By exploring the characterization, classification, synthesis, targeting strategies, and advantages of LBNPs, this study highlights how LBNPs have been used to overcome the limitations of traditional chemotherapy and improve patient outcomes. As nanotechnology revolutionizes cancer therapy, the emergence of LBNPs as a promising strategy for targeted drug delivery has led to optimism regarding the future of cancer treatment. This review extensively assesses the structure, categories, production methods, targeting strategies, benefits, and recent advancements in LBNPs for treating cancer. It also highlights current challenges and possible future directions. This review is aimed at providing a comprehensive understanding of LBNPs’ potential in cancer therapy. Liposomes, nanostructured lipid carriers, solid lipid nanoparticles, and lipid-polymer hybrid nanoparticles are all types of LBNPs, each with unique features of interest for cancer therapy. These particles can be synthesized through various procedures, such as bulk nanoprecipitation, solvent-based emulsification, or microfluidics. Passive targeting systems, active targeting systems, and responsive delivery platforms direct LBNPs to tumors. Consequently, LBNPs provide an improved drug release pattern that minimizes side effects while enhancing therapeutic efficacy. With the potential for combination therapy, LBNPs offer a hopeful future for cancer treatment. Continued research is expected to improve patient outcomes and overall quality of life in cancer care.

Keywords

cancer nano therapy / LBNPs / targeted drug delivery

References

[1] WHO. Cancer. Available from: https://www.who.int/health-topics/cancer#tab=tab_1. [Accessed on 3 Jun 2024]

[2] World Cancer Day 2023: Close the care gap - PAHO/WHO. Pan American Health Organization. Available from: https://www.paho.org/en/campaigns/world-cancer-day-2023-close-care-gap. [Accessed on 3 Jun 2024]

[3] WHO. Cancer today. Available from: https://gco.iarc.who.int/today/en/dataviz/bars?mode=cancer&key=total&group_populations=1&types=0_1&sort_by=value1&populations=900&multiple_populations=0&values_position=out&cancers_h=39. [accessed on 3 Jun 2024]

[4] THE 17 GOALS. Sustainable development. Available from: https://sdgs.un.org/goals. [accessed on 12 Jun 2024]

[5] Jabir NR, Tabrez S, Ashraf GM, Shakil S, Damanhouri GA, et al. Nanotechnology-based approaches in anticancer research. Int J Nanomedicine 2012; 7: 4391-408. [PMID: 22927757 DOI: 10.2147/IJN.S33838]

[6] Xu M, Han X, Xiong H, Gao Y, Xu B, et al. Cancer nanomedicine: emerging strategies and therapeutic potentials. Molecules 2023; 28: 5145. [PMID: 37446806 DOI: 10.3390/molecules28135145]

[7] Canadian Cancer Society. How cancer starts, grows and spreads. Available from: https://cancer.ca/en/cancer-information/what-is-cancer/how-cancer-starts-grows-and-spreads. [Accessed on 3 Jun 2024].

[8] Anand U, Dey A, Chandel AKS, Sanyal R, Mishra A, et al. Cancer chemotherapy and beyond: current status, drug candidates, associated risks and progress in targeted therapeutics. Genes Dis 2023; 10: 1367-401. [PMID: 37397557 DOI: 10.1016/j.gendis.2022.02.007]

[9] Lorscheider M, Gaudin A, Nakhle J, Veiman KL, Richard J, et al. Challenges and opportunities in the delivery of cancer therapeutics: update on recent progress. Ther Deliv 2021; 12: 55-76. [PMID: 33307811 DOI: 10.4155/tde-2020-0079]

[10] Debela DT, Muzazu SGY, Heraro KD, Ndalama MT, Mesele BW, et al. New approaches and procedures for cancer treatment: current perspectives. SAGE Open Med 2021; 9: 20503121211034366. [PMID: 34408877 DOI: 10.1177/20503121211034366]

[11] Thangavelu L, Imran M, Alsharari SH, Abdulaziz AM, Alawlaqi AM, et al. Exploring hypoxia-induced ncRNAs as biomarkers and therapeutic targets in lung cancer. Pathol Res Pract 2024; 263: 155613. [PMID: 39383737 DOI: 10.1016/j.prp.2024.155613]

[12] NCI. Side effects of cancer treatment. Available from: https://www.cancer.gov/about-cancer/treatment/side-effects. [Accessed on 12 Jun 2024]

[13] Jin C, Wang K, Oppong-Gyebi A, Hu J. Application of nanotechnology in cancer diagnosis and therapy - a mini-review. Int J Med Sci 2020; 17: 2964-73. [PMID: 33173417 DOI: 10.7150/ijms.49801]

[14] Loh JS, Tan LKS, Lee WL, Ming LC, How CW, et al. Do lipid-based nanoparticles hold promise for advancing the clinical translation of anticancer alkaloids? Cancers 2021; 13: 5346. [PMID: 34771511 DOI: 10.3390/cancers13215346]

[15] Kemp JA, Kwon YJ. Cancer nanotechnology: current status and perspectives. Nano Converg 2021; 8: 1-38. [PMID: 34727233 DOI: 10.1186/s40580-021-00282-7]

[16] Sheoran S, Arora S, Samsonraj R, Govindaiah P, Vuree S. Lipid-based nanoparticles for treatment of cancer. Heliyon 2022; 8: e09403. [PMID: 35663739 DOI: 10.1016/j.heliyon.2022.e09403]

[17] Zhao C, Zhu X, Tan J, Mei C, Cai X, et al. Lipid-based nanoparticles to address the limitations of GBM therapy by overcoming the blood-brain barrier, targeting glioblastoma stem cells, and counteracting the immunosuppressive tumor microenvironment. Biomed Pharmacother 2024; 171: 116113. [PMID: 38181717 DOI: 10.1016/j.biopha.2023.116113]

[18] Waheed I, Ali A, Tabassum H, Khatoon N, Lai WF, et al. Lipid-based nanoparticles as drug delivery carriers for cancer therapy. Front Oncol 2024; 14: 1296091. [PMID: 38660132 DOI: 10.3389/fonc.2024.1296091]

[19] Aresh W, Liu Y, Sine J, Thayer D, Puri A, et al. The morphology of self-assembled lipid-based nanoparticles affects their uptake by cancer cells. J Biomed Nanotechnol 2016; 12: 1852-63. [PMID: 29359898 DOI: 10.1166/jbn.2016.2292]

[20] Chen W, Duša F, Witos J, Ruokonen SK, Wiedmer SK. Determination of the main phase transition temperature of phospholipids by nanoplasmonic sensing. Sci Rep 2018; 8: 14815. [PMID: 30287903 DOI: 10.1038/s41598-018-33107-5]

[21] Tenchov R, Bird R, Curtze AE, Zhou Q. Lipid nanoparticles from liposomes to mRNA vaccine delivery, a landscape of research diversity and advancement. ACS Nano 2021; 15: 16982-7015. [PMID: 34181394 DOI: 10.1021/acsnano.1c04996]

[22] Zeng S, Chen Y, Zhou F, Zhang T, Fan X, et al. Recent advances and prospects for lipid-based nanoparticles as drug carriers in the treatment of human retinal diseases. Adv Drug Deliv Rev 2023; 199: 114965. [PMID: 37315899 DOI: 10.1016/j.addr.2023.114965]

[23] Zhigaltsev IV, Cullis PR. Morphological behavior of liposomes and lipid nanoparticles. Langmuir 2023; 39: 3185-93. [PMID: 36812413 DOI: 10.1021/acs.langmuir.2c02794]

[24] Danaei M, Dehghankhold M, Ataei S, Hasanzadeh Davarani F, Javanmard R, et al. Impact of particle size and polydispersity index on the clinical applications of lipidic nanocarrier systems. Pharmaceutics 2018; 10: 57. [PMID: 29783687 DOI: 10.3390/pharmaceutics10020057]

[25] Rommasi F, Esfandiari N. Liposomal nanomedicine: applications for drug delivery in cancer therapy. Nanoscale Res Lett. 2021; 16: 1-20. [PMID: 34032937 DOI: 10.1186/s11671-021-03553-8]

[26] Jakubek ZJ, Chen S, Zaifman J, Tam YYC, Zou S. Lipid nanoparticle and liposome reference materials: assessment of size homogeneity and long-term −70 °C and 4 °C storage stability. Langmuir 2023; 39: 2509-19. [PMID: 36748988 DOI: 10.1021/acs.langmuir.2c02657]

[27] Nsairat H, Khater D, Sayed U, Odeh F, Al Bawab A, et al. Liposomes: structure, composition, types, and clinical applications. Heliyon 2022; 8: e09394. [PMID: 35600452 DOI: 10.1016/j.heliyon.2022.e09394]

[28] Yingchoncharoen P, Kalinowski DS, Richardson DR. Lipid-based drug delivery systems in cancer therapy: what is available and what is yet to come. Pharmacol Rev 2016; 68: 701-87. [PMID: 27363439 DOI: 10.1124/pr.115.012070]

[29] Graewert MA, Wilhelmy C, Bacic T, Schumacher J, Blanchet C, et al. Quantitative size-resolved characterization of mRNA nanoparticles by in-line coupling of asymmetrical-flow field-flow fractionation with small angle X-ray scattering. Sci Rep 2023; 13: 15764. [PMID: 37737457 DOI: 10.1038/s41598-023-42274-z]

[30] Mehta M, Bui TA, Yang X, Aksoy Y, Goldys EM, et al. Lipid-based nanoparticles for drug/gene delivery: an overview of the production techniques and difficulties encountered in their industrial development. ACS Mater Au 2023; 3: 600-19. [PMID: 38089666 DOI: 10.1021/acsmaterialsau.3c00032]

[31] Fernandez-Fernandez A, Manchanda R, Kumari M . Lipid-engineered nanotherapeutics for cancer management. Front Pharmacol 2023; 14: 1125093. [PMID: 37033603 DOI: 10.3389/fphar.2023.1125093]

[32] Wang MM, Wappelhorst CN, Jensen EL, Thomas Chi YC, Rouse JC, et al. Elucidation of lipid nanoparticle surface structure in mRNA vaccines. Sci Rep 2023; 13: 16744. [PMID: 37798336 DOI: 10.1038/s41598-023-43898-x]

[33] Jasim SA, Ahmed AT, Kubaev A, Kyada A, Alshahrani MY, et al. Exosomal microRNA as a key regulator of PI3K/AKT pathways in human tumors. Med Oncol 2024; 41: 265. [PMID: 39400677 DOI: 10.1007/s12032-024-02529-9]

[34] Zhang C, Ma Y, Zhang J, Kuo JC, Zhang Z, et al. Modification of lipid-based nanoparticles: an efficient delivery system for nucleic acid-based immunotherapy. Molecules 2022; 27: 1943. [PMID: 35335310 DOI: 10.3390/molecules27061943]

[35] García-Pinel B, Porras-Alcalá C, Ortega-Rodríguez A, Sarabia F, Prados J, et al. Lipid-based nanoparticles: application and recent advances in cancer treatment. Nanomaterials 2019; 9: 638. [PMID: 31010180 DOI: 10.3390/nano9040638]

[36] Akombaetwa N, Ilangala AB, Thom L, Memvanga PB, Witika BA, et al. Current advances in lipid nanosystems intended for topical and transdermal drug delivery applications. Pharmaceutics 2023; 15: 656. [PMID: 36839978 DOI: 10.3390/pharmaceutics15020656]

[37] Liu Y, Zhang N. Gadolinium loaded nanoparticles in theranostic magnetic resonance imaging. Biomaterials 2012; 33: 5363-75. [PMID: 22521487 DOI: 10.1016/j.biomaterials.2012.03.084]

[38] Lombardo D, Kiselev MA. Methods of liposomes preparation: formation and control factors of versatile nanocarriers for biomedical and nanomedicine application. Pharmaceutics 2022; 14: 543. [PMID: 35335920 DOI: 10.3390/pharmaceutics14030543]

[39] Eibl H. Phospholipids as functional constituents of biomembranes. Angew Chem Int Ed Engl 1984; 23: 257-71. [DOI: 10.1002/anie.198402573]

[40] Phospholipid Research Center . The various phospholipid aggregates. Available from: https://www.phospholipid-research-center.com/phospholipid/aggregates/. [Accessed on 26 Jun 2024]

[41] Chowdhury S, Yusof F, Salim WW, Sulaiman N, Faruck MO. An overview of drug delivery vehicles for cancer treatment: nanocarriers and nanoparticles including photovoltaic nanoparticles. J Photochem Photobiol B 2016; 164: 151-9. [PMID: 27683958 DOI: 10.1016/j.jphotobiol.2016.09.013]

[42] Birhanu G, Javar HA, Seyedjafari E, Zandi-Karimi A. Nanotechnology for delivery of gemcitabine to treat pancreatic cancer. Biomed Pharmacother 2017; 88: 635-43. [PMID: 28142120 DOI: 10.1016/j.biopha.2017.01.071]

[43] Li J, Wang Q, Xia G, Adilijiang N, Li Y, et al. Recent advances in targeted drug delivery strategy for enhancing oncotherapy. Pharmaceutics 2023; 15: 2233. [PMID: 37765202 DOI: 10.3390/pharmaceutics15092233]

[44] Nakhaei P, Margiana R, Bokov DO, Abdelbasset WK, Jadidi Kouhbanani MA, et al. Liposomes: structure, biomedical applications, and stability parameters with emphasis on cholesterol. Front Bioeng Biotechnol 2021; 9: 705886. [PMID: 34568298 DOI: 10.3389/fbioe.2021.705886]

[45] Liu P, Chen G, Zhang J. A review of liposomes as a drug delivery system: current status of approved products, regulatory environments, and future perspectives. Molecules 2022; 27: 1372. [PMID: 35209162 DOI: 10.3390/molecules27041372]

[46] Andra VVSNL, Pammi SVN, Bhatraju LVKP, Ruddaraju LK. A comprehensive review on novel liposomal methodologies, commercial formulations, clinical trials and patents. Bionanoscience 2022; 12: 274-91. [PMID: 35096502 DOI: 10.1007/s12668-022-00941-x]

[47] Priyadarshani A. Advantages and disadvantages of solid lipid nanoparticles. J Nanomed Biother Discov 2022; 12: 173. [DOI: 10.4172/2155-983X.22.12.173]

[48] Subroto E, Andoyo R, Indiarto R. Solid lipid nanoparticles: review of the current research on encapsulation and delivery systems for active and antioxidant compounds. Antioxidants 2023; 12: 633. [PMID: 36978881 DOI: 10.3390/antiox12030633]

[49] Nguyen VH, Thuy VN, Van TV, Dao AA, Lee BJ. Nanostructured lipid carriers and their potential applications for versatile drug delivery via oral administration. OpenNano 2022; 8: 100064. [DOI: 10.1016/j.onano.2022.100064]

[50] Jaiswal P, Gidwani B, Vyas A. Nanostructured lipid carriers and their current application in targeted drug delivery. Artif Cells Nanomed Biotechnol 2016; 44: 27-40. [PMID: 24813223 DOI: 10.3109/21691401.2014.909822]

[51] Jain S, Kumar M, Kumar P, Verma J, Rosenholm JM, et al. Lipid-polymer hybrid nanosystems: a rational fusion for advanced therapeutic delivery. J Funct Biomater 2023; 14: 437. [PMID: 37754852 DOI: 10.3390/jfb14090437]

[52] Gajbhiye KR, Salve R, Narwade M, Sheikh A, Kesharwani P, et al. Lipid polymer hybrid nanoparticles: a custom-tailored next-generation approach for cancer therapeutics. Mol Cancer 2023; 22: 160. [PMID: 37784179 DOI: 10.1186/s12943-023-01849-0]

[53] Vishwakarma DK, Mishra JN, Shukla AK, Singh AP. Phytosomes as a novel approach to drug delivery system. 2024. [DOI: 10.5772/INTECHOPEN.113914]

[54] Dutt Y, Pandey RP, Dutt M, Gupta A, Vibhuti A, et al. Liposomes and phytosomes: nanocarrier systems and their applications for the delivery of phytoconstituents. Coord Chem Rev 2023; 491: 215251. [DOI: 10.1016/j.ccr.2023.215251]

[55] LaBauve AE, Saada EA, Jones IKA, Mosesso R, Noureddine A, et al. Lipid-coated mesoporous silica nanoparticles for anti-viral applications via delivery of CRISPR-Cas9 ribonucleoproteins. Sci Rep 2023; 13: 6873. [PMID: 37105997 DOI: 10.1038/s41598-023-33092-4]

[56] Wang Y, Cheng WY, Zhu J, He L, Ren W, et al. Programmed Co-delivery of tamoxifen and docetaxel using lipid-coated mesoporous silica nanoparticles for overcoming CYP3A4-mediated resistance in triple-negative breast cancer treatment. Biomed Pharmacother 2024; 170: 116084. [PMID: 38157645 DOI: 10.1016/j.biopha.2023.116084]

[57] Bulbake U, Doppalapudi S, Kommineni N, Khan W. Liposomal formulations in clinical use: an updated review. Pharmaceutics 2017; 9: 12. [PMID: 28346375 DOI: 10.3390/pharmaceutics9020012]

[58] Pandey S, Shaikh F, Gupta A, Tripathi P, Yadav JS. A recent update: solid lipid nanoparticles for effective drug delivery. Adv Pharm Bull 2022; 12: 17-33. [PMID: 35517874 DOI: 10.34172/apb.2022.007]

[59] Mirchandani Y, Patravale VB, Brijesh S . Solid lipid nanoparticles for hydrophilic drugs. J Control Release 2021; 335: 457-64. [PMID: 34048841 DOI: 10.1016/j.jconrel.2021.05.032]

[60] Mukherjee S, Ray S, Thakur RS. Solid lipid nanoparticles: a modern formulation approach in drug delivery system. Indian J Pharm Sci 2009; 71: 349-58. [PMID: 20502539 DOI: 10.4103/0250-474X.57282]

[61] Nguyen TTL, Duong VS. Solid lipid nanoparticles. Encyclopedia 2022; 2: 952-73. [DOI: 10.3390/encyclopedia2020063]

[62] Xu L, Wang X, Liu Y, Yang G, Falconer RJ, et al. Lipid nanoparticles for drug delivery. Adv Nanobiomed Res 2022; 2: 2100109. [DOI: 10.1002/anbr.202100109]

[63] Satapathy MK, Yen TL, Jan JS, Tang RD, Wang JY, et al. Solid lipid nanoparticles (SLNs): an advanced drug delivery system targeting brain through BBB. Pharmaceutics 2021; 13: 1183. [PMID: 34452143 DOI: 10.3390/pharmaceutics13081183]

[64] Bukke SPN, Venkatesh C, Bandenahalli Rajanna S, Saraswathi TS, Kusuma PK, et al. Solid lipid nanocarriers for drug delivery: design innovations and characterization strategies-a comprehensive review. Discover Appl Sci 2024; 6: 279. [DOI: 10.1007/s42452-024-05897-z]

[65] Duong VA, Nguyen TTL, Maeng HJ. Preparation of solid lipid nanoparticles and nanostructured lipid carriers for drug delivery and the effects of preparation parameters of solvent injection method. Molecules 2020; 25: 4781. [PMID: 33081021 DOI: 10.3390/molecules25204781]

[66] Madkhali OA. Perspectives and prospective on solid lipid nanoparticles as drug delivery systems. Molecules 2022; 27: 1543. [PMID: 35268643 DOI: 10.3390/molecules27051543]

[67] Sivadasan D, Ramakrishnan K, Mahendran J, Ranganathan H, Karuppaiah A, et al. Solid lipid nanoparticles: applications and prospects in cancer treatment. Int J Mol Sci 2023; 24: 6199. [PMID: 37047172 DOI: 10.3390/ijms24076199]

[68] Cai X, Zhai J, Tran N, Mulet X, Drummond CJ. Lipid nanoparticle steric stabilization roadmap. Adv Biomembr Lipid Self-Assem 2022; 35: 41-75. [DOI: 10.1016/bs.abl.2022.05.003]

[69] Viegas C, Seck F, Fonte P. An insight on lipid nanoparticles for therapeutic proteins delivery. J Drug Deliv Sci Technol 2022; 77: 103839. [DOI: 10.1016/j.jddst.2022.103839]

[70] Ghasemiyeh P, Mohammadi-Samani S. Solid lipid nanoparticles and nanostructured lipid carriers as novel drug delivery systems: applications, advantages and disadvantages. Res Pharm Sci 2018; 13: 288-303. [PMID: 30065762 DOI: 10.4103/1735-5362.235156]

[71] Duan Y, Dhar A, Patel C, Khimani M, Neogi S, et al. A brief review on solid lipid nanoparticles: part and parcel of contemporary drug delivery systems. RSC Adv 2020; 10: 26777-91. [PMID: 35515778 DOI: 10.1039/d0ra03491f]

[72] Javed S, Mangla B, Almoshari Y, Sultan MH, Ahsan W. Nanostructured lipid carrier system: a compendium of their formulation development approaches, optimization strategies by quality by design, and recent applications in drug delivery. Nanotechnol Rev 2022; 11: 1744-77. [DOI: 10.1515/ntrev-2022-0109]

[73] Viegas C, Patrício AB, Prata JM, Nadhman A, Chintamaneni PK, et al. Solid lipid nanoparticles vs. nanostructured lipid carriers: a comparative review. Pharmaceutics 2023; 15: 1593. [PMID: 37376042 DOI: 10.3390/pharmaceutics15061593]

[74] Khosa A, Reddi S, Saha RN. Nanostructured lipid carriers for site-specific drug delivery. Biomed Pharmacother 2018; 103: 598-613. [PMID: 29677547 DOI: 10.1016/j.biopha.2018.04.055]

[75] Garg J, Pathania K, Sah SP, Pawar SV. Nanostructured lipid carriers: a promising drug carrier for targeting brain tumours. Future J Pharm Sci 2022; 8: 1-31. [DOI: 10.1186/s43094-022-00414-8]

[76] Parveen S, Gupta P, Kumar S, Banerjee M. Lipid polymer hybrid nanoparticles are potent vehicles for drug delivery in cancer therapeutics. Med Drug Discov 2023; 20: 100165. [DOI: 10.1016/j.medidd.2023.100165]

[77] Zielińska A, Carreiró F, Oliveira AM, Neves A, Pires B, et al. Polymeric nanoparticles: production, characterization, toxicology and ecotoxicology. Molecules 2020; 25: 3731. [PMID: 32824172 DOI: 10.3390/molecules25163731]

[78] Sivadasan D, Sultan MH, Madkhali O, Almoshari Y, Thangavel N. Polymeric lipid hybrid nanoparticles (PLNs) as emerging drug delivery platform - a comprehensive review of their properties, preparation methods, and therapeutic applications. Pharmaceutics 2021; 13: 1291. [PMID: 34452251 DOI: 10.3390/pharmaceutics13081291]

[79] Mukherjee A, Waters AK, Kalyan P, Achrol AS, Kesari S, et al. Lipid-polymer hybrid nanoparticles as a next-generation drug delivery platform: state of the art, emerging technologies, and perspectives. Int J Nanomedicine 2019; 14: 1937-52. [PMID: 30936695 DOI 10.2147/IJN.S198353]

[80] Bangera PD, Kara DD, Tanvi K, Tippavajhala VK, Rathnanand M. Highlights on cell-penetrating peptides and polymer-lipid hybrid nanoparticle: overview and therapeutic applications for targeted anticancer therapy. AAPS PharmSciTech 2023; 24: 1-24. [PMID: 37225901 DOI: 10.1208/s12249-023-02576-x]

[81] Alharbi WS, Almughem FA, Almehmady AM, Jarallah SJ, Alsharif WK, et al. Phytosomes as an emerging nanotechnology platform for the topical delivery of bioactive phytochemicals. Pharmaceutics 2021; 13: 1475. [PMID: 34575551 DOI: 10.3390/pharmaceutics13091475]

[82] Gaikwad SS, Morade YY, Kothule AM, Kshirsagar SJ, Laddha UD, et al. Overview of phytosomes in treating cancer: advancement, challenges, and future outlook. Heliyon 2023; 9: e16561. [PMID: 37260890 DOI: 10.1016/j.heliyon.2023.e16561]

[83] Chaudhary K, Rajora A. Phytosomes: a critical tool for delivery of herbal drugs for cancer: phytosomes: advancing herbal medicine delivery. Phytochem Rev 2024; 1-31. [DOI: 10.1007/s11101-024-09947-7]

[84] Manthena S, Srinivas P, Sadanandam. Phytosomes in herbal drug delivery. J Nat Pharm 2010; 1: 14.

[85] Barani M, Sangiovanni E, Angarano M, Rajizadeh MA, Mehrabani M, et al. Phytosomes as innovative delivery systems for phytochemicals: a comprehensive review of literature. Int J Nanomedicine 2021; 16: 6983-7022. [PMID: 34703224 DOI: 10.2147/IJN.S318416]

[86] Dewi MK, Chaerunisaa AY, Muhaimin M, Joni IM. Improved activity of herbal medicines through nanotechnology. Nanomaterials 2022; 12: 4073. [PMID: 36432358 DOI: 10.3390/nano12224073]

[87] Hashemzadeh H, Hanafi-Bojd MY, Iranshahy M, Zarban A, Raissi H. The combination of polyphenols and phospholipids as an efficient platform for delivery of natural products. Sci Rep 2023; 13: 1-20. [DOI: 10.1038/s41598-023-29237-0]

[88] Shriram RG, Moin A, Alotaibi HF, Khafagy ES, Al Saqr A, et al. Phytosomes as a plausible nano-delivery system for enhanced oral bioavailability and improved hepatoprotective activity of silymarin. Pharmaceuticals 2022; 15: 790. [PMID: 35890088 DOI: 10.3390/ph15070790]

[89] Lu M, Qiu Q, Luo X, Liu X, Sun J, et al. Phyto-phospholipid complexes (phytosomes): a novel strategy to improve the bioavailability of active constituents. Asian J Pharm Sci 2019; 14: 265-74. [PMID: 32104457 DOI: 10.1016/j.ajps.2018.05.011]

[90] Haripriyaa M, Suthindhiran K. Pharmacokinetics of nanoparticles: current knowledge, future directions and its implications in drug delivery. Futur J Pharm Sci 2023; 9: 1-26. [DOI: 10.1186/s43094-023-00569-y]

[91] Google Books. Lipid-based drug delivery systems: principles and applications. Available from: https://books.google.co.in/books?hl=en&lr=&id=yyTcEAAAQBAJ&oi=fnd&pg=PP1&dq=Lipid-coated+nanoparticles+are+a+valuable+class+of+drug+delivery+systems+that+are+minuscule+particles+encased+in+a+layer+of+lipid,+or+fat+to+enhance+medication+delivery+to+certain+anatomical+sites.&ots=BSbyUxOhf6&sig=qt0eop0Wd3AqhxlxIrEtQs48-Ns&redir_esc=y#v=onepage&q&f=false. [Accessed on 27 Jul 2024]

[92] Simons K. Cell membranes: a subjective perspective. Biochim Biophys Acta 2016; 1858: 2569-72. [PMID: 26827711 DOI: 10.1016/j.bbamen.2016.01.023]

[93] Krishnamurthy S, Vaiyapuri R, Zhang L, Chan JM. Lipid-coated polymeric nanoparticles for cancer drug delivery. Biomater Sci 2015; 3: 923-36. [PMID: 26221931 DOI: 10.1039/c4bm00427b]

[94] Schubert J, Chanana M. Coating matters: review on colloidal stability of nanoparticles with biocompatible coatings in biological media, living cells and organisms. Curr Med Chem 2018; 25: 4553-86. [PMID: 29852857 DOI: 10.2174/0929867325666180601101859]

[95] Bothun GD. Hydrophobic silver nanoparticles trapped in lipid bilayers: size distribution, bilayer phase behavior, and optical properties. J Nanobiotechnology 2008; 6: 13. [PMID: 19014492 DOI: 10.1186/1477-3155-6-13]

[96] Mitchell MJ, Billingsley MM, Haley RM, Haley RM, Wechsler ME, et al. Engineering precision nanoparticles for drug delivery. Nat Rev Drug Discov 2020; 20: 101-24. [PMID: 33277608 DOI: 10.1038/s41573-020-0090-8]

[97] Fessi H, Puisieux F, Devissaguet JP, Ammoury N, Benita S. Nanocapsule formation by interfacial polymer deposition following solvent displacement. Int J Pharm 1989; 55: R1-4. [DOI: 10.1016/0378-5173(89)90281-0]

[98] Forys A, Chountoulesi M, Mendrek B, Konieczny T, Sentoukas T, et al. The influence of hydrophobic blocks of PEO-containing copolymers on glyceryl monooleate lyotropic liquid crystalline nanoparticles for drug delivery. Polymers (Basel) 2021; 13: 2607. [PMID: 34451146 DOI: 10.3390/polym13162607]

[99] Salatin S, Barar J, Barzegar-Jalali M, Adibkia K, Kiafar F, et al. Development of a nanoprecipitation method for the entrapment of a very water soluble drug into Eudragit RL nanoparticles. Res Pharm Sci 2017; 12: 1-14. [PMID: 28255308 DOI: 10.4103/1735-5362.199041]

[100] Mekuye B, Abera B. Nanomaterials: an overview of synthesis, classification, characterization, and applications. Nano Select 2023; 4: 486-501. [DOI: 10.1002/nano.202300038]

[101] Napiórkowska A, Kurek M. Coacervation as a novel method of microencapsulation of essential oils-a review. Molecules 2022; 27: 5142. [PMID: 36014386 DOI: 10.3390/molecules27165142]

[102] Moulik SP, Rakshit AK, Pan A, Naskar B. An overview of coacervates: the special disperse state of amphiphilic and polymeric materials in solution. Colloids Interface 2022; 6: 45. [DOI: 10.3390/colloids6030045]

[103] Keller S, Teora SP, Boujemaa M, Wilson DA. Exploring new horizons in liquid compartmentalization via microfluidics. Biomacromolecules 2021; 22: 1759-69. [PMID: 33835788 DOI: 10.1021/acs.biomac.0c01796]

[104] Hernández-Esquivel R-A, Navarro-Tovar G, Zárate-Hernández E, Aguirre-Bañuelos P. Solid lipid nanoparticles (SLN). In: Nanocomposite materials for biomedical and energy storage applications. IntechOpen. [DOI: 10.5772/INTECHOPEN.102536h]

[105] Talarico L, Consumi M, Leone G, Tamasi G, Magnani A. Solid lipid nanoparticles produced via a coacervation method as promising carriers for controlled release of quercetin. Molecules 2021; 26: 2694. [PMID: 34064488 DOI: 10.3390/molecules26092694]

[106] Jain E, Tripathi AD, Agarwal A, Maurya KK, Rai DC, et al. Anticancerous compounds in fruits, their extraction, and relevance to food. In: Functional foods and nutraceuticals in metabolic and non-communicable diseases. 2022. pp. 517-532. [DOI: 10.1016/B978-0-12-819815-5.00022-7]

[107] Lohcharoenkal W, Wang L, Chen YC, Rojanasakul Y. Protein nanoparticles as drug delivery carriers for cancer therapy. Biomed Res Int 2014; 2014: 180549. [PMID: 24772414 DOI: 10.1155/2014/180549]

[108] Koroleva M, Portnaya I, Mischenko E, Abutbul-Ionita I, Kolik-Shmuel L, et al. Solid lipid nanoparticles and nanoemulsions with solid shell: physical and thermal stability. J Colloid Interface Sci 2022; 610: 61-9. [PMID: 34922082 DOI: 10.1016/j.jcis.2021.12.010]

[109] Vladisavljević GT. Preparation of microemulsions and nanoemulsions by membrane emulsification. Colloids Surf A Physicochem Eng Asp 2019; 579: 123709. [DOI: 10.1016/j.colsurfa.2019.123709]

[110] Jaradat E, Weaver E, Meziane A, Lamprou DA. Microfluidics technology for the design and formulation of nanomedicines. Nanomaterials 2021; 11: 3440. [PMID: 34947789 DOI: 10.3390/nano11123440]

[111] Owodeha-Ashaka K, Ilomuanya MO, Iyire A. Evaluation of sonication on stability-indicating properties of optimized pilocarpine hydrochloride-loaded niosomes in ocular drug delivery. Prog Biomater 2021; 10: 207-20. [PMID: 34549376 DOI: 10.1007/s40204-021-00164-5]

[112] de Freitas CF, Pellosi DS, Tessaro AL. Lipid-based nanoparticles in photodynamic therapy. Nanomater Photodyn Ther 2023; 203-226. [DOI: 10.1016/B978-0-323-85595-2.00006-2]

[113] Gimondi S, Ferreira H, Reis RL, Neves NM. Microfluidic devices: a tool for nanoparticle synthesis and performance evaluation. ACS Nano 2023; 17: 14205-28. [PMID: 37498731 DOI: 10.1021/acsnano.3c01117]

[114] Bezelya AA, Küçüktürkmen B, Bozkır A. Microfluidic devices for precision nanoparticle production. Micro 2023; 3: 822-66. [DOI: 10.3390/micro3040058]

[115] Thomée E. Microfluidic nanoparticle synthesis: a short review. Elveflow . Available from: https://www.elveflow.com/microfluidic-reviews/general-microfluidics/microfluidic-nanoparticle-synthesis-short-review/. [ 2021, accessed on 30 Jul 2024]

[116] Liu Y, Yang G, Hui Y, Ranaweera S, Zhao CX. Microfluidic nanoparticles for drug delivery. Small 2022; 18: 2106580. [PMID: 35396770 DOI: 10.1002/smll.202106580]

[117] Maged A, Abdelbaset R, Mahmoud AA, Elkasabgy NA . Merits and advances of microfluidics in the pharmaceutical field: design technologies and future prospects. Drug Deliv 2022; 29: 1549-70. [PMID: 35612293 DOI: 10.1080/10717544.2022.2069878]

[118] Khizar S, Zine N, Errachid A, Jaffrezic-Renault N, Elaissari A. Microfluidic-based nanoparticle synthesis and their potential applications. Electrophoresis 2022; 43: 819-38. [PMID: 34758117 DOI: 10.1002/elps.202100242]

[119] Niculescu AG, Mihaiescu DE, Grumezescu AM. A review of microfluidic experimental designs for nanoparticle synthesis. Int J Mol Sci 2022; 23: 8293. [PMID: 35955420 DOI: 10.3390/ijms23158293]

[120] Agha A, Waheed W, Stiharu I, Nerguizian V, Destgeer G, et al. A review on microfluidic-assisted nanoparticle synthesis, and their applications using multiscale simulation methods. Discover Nano 2023; 18: 1-54. [PMID: 36800044 DOI: 10.1186/s11671-023-03792-x]

[121] Bhalani DV, Nutan B, Kumar A, Singh Chandel AK. Bioavailability enhancement techniques for poorly aqueous soluble drugs and therapeutics. Biomedicines 2022; 10: 2055. [PMID: 36140156 DOI: 10.3390/biomedicines10092055]

[122] Khairnar SV, Pagare P, Thakre A, Nambiar AR, Junnuthula V, et al. Review on the scale-up methods for the preparation of solid lipid nanoparticles. Pharmaceutics 2022; 14: 1886. [PMID: 36145632 DOI: 10.3390/pharmaceutics14091886]

[123] Trotta M, Debernardi F, Caputo O. Preparation of solid lipid nanoparticles by a solvent emulsification-diffusion technique. Int J Pharm 2003; 257: 153-60. [PMID: 12711170 DOI: 10.1016/s0378-5173(03)00135-2]

[124] Patel KK, Gade S, Anjum MM, Singh SK, Maiti P, et al. Effect of penetration enhancers and amorphization on transdermal permeation flux of raloxifene-encapsulated solid lipid nanoparticlean ex vivo study on human skin. Appl Nanosci (Switzerland) 2019; 9: 1383-94. [DOI: 10.1007/s13204-019-01004-6]

[125] Pooja D, Kulhari H, Tunki L, Chinde S, Kuncha M, et al. Nanomedicines for targeted delivery of etoposide to non-small cell lung cancer using transferrin functionalized nanoparticles. RSC Adv 2015; 5: 49122-31. [DOI: 10.1039/C5RA03316K]

[126] Mohite P, Singh S, Pawar A, Sangale A, Prajapati BG. Lipid-based oral formulation in capsules to improve the delivery of poorly water-soluble drugs. Front Drug Deliv 2023; 3: 1232012. [DOI: 10.3389/fddev.2023.1232012]

[127] Verma G, Rajagopalan MD, Valluru R, Sridhar KA. Nanoparticles: a novel approach to target tumors. Nano Microscale Drug Deliv Syst 2017; 113-129. [DOI: 10.1016/B978-0-323-52727-9.00007-8]

[128] Montalbán MG, Víllora G. Supercritical fluids: properties and applications. In: Phase equilibria with supercritical carbon dioxide - application to the components of a biocatalytic process. [DOI: 10.5772/INTECHOPEN.105485]

[129] Chakravarty P, Famili A, Nagapudi K, Al-Sayah MA. Using supercritical fluid technology as a green alternative during the preparation of drug delivery systems. Pharmaceutics 2019; 11: 629. [PMID: 31775292 DOI: 10.3390/pharmaceutics11120629]

[130] Misra SK, Pathak K. Supercritical fluid technology for solubilization of poorly water soluble drugs via micro- and naonosized particle generation. ADMET DMPK 2020; 8: 355-74. [PMID: 35300190 DOI: 10.5599/admet.811]

[131] Franco P, De Marco I. Nanoparticles and nanocrystals by supercritical CO₂-assisted techniques for pharmaceutical applications: a review. Appl Sci 2021; 11: 1476. [DOI: 10.3390/app11041476]

[132] Szczyglewska P, Feliczak-Guzik A, Nowak I. Nanotechnology-general aspects: a chemical reduction approach to the synthesis of nanoparticles. Molecules 2023; 28: 4932. [PMID: 37446593 DOI: 10.3390/molecules28134932]

[133] Elumalai K, Srinivasan S, Shanmugam A. Review of the efficacy of nanoparticle-based drug delivery systems for cancer treatment. Biomed Tech 2024; 5: 109-22. [DOI: 10.1016/j.bmt.2023.09.001]

[134] Bazak R, Houri M, Achy SE, Hussein W, Refaat T. Passive targeting of nanoparticles to cancer: a comprehensive review of the literature. Mol Clin Oncol 2014; 2: 904-8. [PMID: 25279172 DOI: 10.3892/mco.2014.356]

[135] Chehelgerdi M, Chehelgerdi M, Allela OQB, Pecho RDC, Jayasankar N, et al. Progressing nanotechnology to improve targeted cancer treatment: overcoming hurdles in its clinical implementation. Mol Cancer 2023; 22: 169. [PMID: 37814270 DOI: 10.1186/s12943-023-01865-0]

[136] Zhao M, Zhu X, Li B, Yan C, Wu C, et al. Potent cancer therapy by liposome microstructure tailoring with active-to-passive targeting and shell-to-core thermosensitive features. Mater Today Bio 2024; 26: 101035. [PMID: 38586871 DOI: 10.1016/j.mtbio.2024.101035]

[137] Shi S, Zhong H, Zhang Y, Mei Q. Targeted delivery of nano-radiosensitizers for tumor radiotherapy. Coord Chem Rev 2024; 518: 216101. [DOI: 10.1016/j.ccr.2024.216101]

[138] Fidan Y, Muçaj S, Timur SS, Gürsoy RN. Recent advances in liposome-based targeted cancer therapy. J Liposome Res 2024; 34: 316-34. [PMID: 37814217 DOI: 10.1080/08982104.2023.2268710]

[139] McCright J, Naiknavare R, Yarmovsky J, Maisel K. Targeting lymphatics for nanoparticle drug delivery. Front Pharmacol 2022; 13: 887402. [PMID: 35721179 DOI: 10.3389/fphar.2022.887402]

[140] Hu M, Li X, You Z, Cai R, Chen C. Physiological barriers and strategies of lipid-based nanoparticles for nucleic acid drug delivery. Adv Mater 2024; 36: 2303266. [PMID: 37792475 DOI: 10.1002/adma.202303266]

[141] Lee J, Choi MK, Song IS. Recent advances in doxorubicin formulation to enhance pharmacokinetics and tumor targeting. Pharmaceuticals 2023; 16: 802. [PMID: 37375753 DOI: 10.3390/ph16060802]

[142] Bajracharya R, Song JG, Patil BR, Lee SH, Noh HM, et al. Functional ligands for improving anticancer drug therapy: current status and applications to drug delivery systems. Drug Deliv 2022; 29: 1959-70. [PMID: 35762636 DOI: 10.1080/10717544.2022.2089296]

[143] Wang J, Li Y, Nie G. Multifunctional biomolecule nanostructures for cancer therapy. Nat Rev Mater 2021; 6: 766-83. [PMID: 34026278 DOI: 10.1038/s41578-021-00315-x]

[144] Rosenblum D, Joshi N, Tao W, Karp JM, Peer D. Progress and challenges towards targeted delivery of cancer therapeutics. Nat Commun 2018; 9: 1410. [PMID: 29650952 DOI: 10.1038/s41467-018-03705-y]

[145] Argenziano M, Arpicco S, Brusa P, Cavalli R, Chirio D, et al. Developing actively targeted nanoparticles to fight cancer: focus on Italian research. Pharmaceutics 2021; 13: 1538. [PMID: 34683830 DOI: 10.3390/pharmaceutics13101538]

[146] Tiwari H, Rai N, Singh S, Gupta P, Verma A, et al. Recent advances in nanomaterials-based targeted drug delivery for preclinical cancer diagnosis and therapeutics. Bioengineering 2023; 10: 760. [PMID: 37508788 DOI: 10.3390/bioengineering10070760]

[147] Sun L, Liu H, Ye Y, Lei Y, Islam R, et al. Smart nanoparticles for cancer therapy. Signal Transduct Target Ther 2023; 8: 418. [PMID: 37919282 DOI: 10.1038/s41392-023-01642-x]

[148] Oehler JB, Rajapaksha W, Albrecht H. Emerging applications of nanoparticles in the diagnosis and treatment of breast cancer. J Pers Med 2024; 14: 723. [PMID: 39063977 DOI: 10.3390/jpm14070723]

[149] Giordano A, Provenza AC, Reverchon G, Baldino L, Reverchon E. Lipid-based nanocarriers: bridging diagnosis and cancer therapy. Pharmaceutics 2024; 16: 1158. [PMID: 39339195 DOI: 10.3390/pharmaceutics16091158]

[150] Ly PD, Ly KN, Phan HL, Nguyen HHT, Duong VA, et al. Recent advances in surface decoration of nanoparticles in drug delivery. Front Nanotech 2024; 6: 1456939. [DOI: 10.3389/fnano.2024.1456939]

[151] Ahmad F, Varghese R, Panda S, Ramamoorthy S, Areeshi MY, et al. Smart nanoformulations for brain cancer theranostics: challenges and promises. Cancers 2022; 14: 5389. [PMID: 36358807 DOI: 10.3390/cancers14215389]

[152] Pham SH, Choi Y, Choi J. Stimuli-responsive nanomaterials for application in antitumor therapy and drug delivery. Pharmaceutics 2020; 12: 630. [PMID: 32635539 DOI: 10.3390/pharmaceutics12070630]

[153] Liu TI, Lu TY, Chang SH, Shen MY, Chiu HC. Dual stimuli-guided lipid-based delivery system of cancer combination therapy. J Control Release 2020; 318: 16-24. [PMID: 31809761 DOI: 10.1016/j.jconrel.2019.12.002]

[154] Samaei SS, Daryab M, Gholami S, Rezaee A, Fatehi N, et al. Multifunctional and stimuli-responsive liposomes in hepatocellular carcinoma diagnosis and therapy. Transl Oncol 2024; 45: 101975. [PMID: 38692195 DOI: 10.1016/j.tranon.2024.101975]

[155] Iqubal MK, Iqubal A, Imtiyaz K, Rizvi MMA, Gupta MM, et al. Combinatorial lipid-nanosystem for dermal delivery of 5-fluorouracil and resveratrol against skin cancer: delineation of improved dermatokinetics and epidermal drug deposition enhancement analysis. Eur J Pharm Biopharm 2021; 163: 223-39. [PMID: 33864904 DOI: 10.1016/j.ejpb.2021.04.007]

[156] Tang H, Xie Y, Zhu M, Jia J, Liu R, et al. Estrone-conjugated PEGylated liposome co-loaded paclitaxel and carboplatin improve anti-tumor efficacy in ovarian cancer and reduce acute toxicity of chemo-drugs. Int J Nanomedicine 2022; 17: 3013-41. [PMID: 35836838 DOI: 10.2147/IJN.S362263]

[157] Jalilian M, Derakhshandeh K, Kurd M, Lashani H. Targeting solid lipid nanoparticles with anisamide for docetaxel delivery to prostate cancer: preparation, optimization, and in-vitro evaluation. Iran J Pharm Res2021; 20: 327-38. [PMID: 34400962 DOI: 10.22037/ijpr.2020.113436.14302]

[158] Chand P, Kumar H, Badduri N, Gupta NV, Bettada VG, et al. Design and evaluation of cabazitaxel loaded NLCs against breast cancer cell lines. Colloids Surf B Biointerfaces 2021; 199: 111535. [PMID: 33360926 DOI: 10.1016/j.colsurfb.2020.111535]

[159] Sadati Behbahani E, Ghaedi M, Abbaspour M, Rostamizadeh K, Dashtian K. Curcumin loaded nanostructured lipid carriers: in vitro digestion and release studies. Polyhedron 2019; 164: 113-22. [DOI: 10.1016/j.poly.2019.02.002]

[160] Wang JY, Song YQ, Peng J, Luo HL. Nanostructured lipid carriers delivering sorafenib to enhance immunotherapy induced by doxorubicin for effective esophagus cancer therapy. ACS Omega 2020; 5: 22840-6. [PMID: 32954132 DOI: 10.1021/acsomega.0c02072]

[161] Talaat SM, Elnaggar YSR, Gowayed MA, El-Ganainy SO, Allam M, et al. Novel PEGylated cholephytosomes for targeting fisetin to breast cancer: in vitro appraisal and in vivo antitumoral studies. Drug Deliv Transl Res 2024; 14: 433-54. [PMID: 37644299 DOI: 10.1007/s13346-023-01409-5]

[162] Aloss K, Hamar P. Recent Preclinical and Clinical Progress in Liposomal Doxorubicin. Pharmaceutics 2023; 15: 893. [PMID: 36986754 DOI: 10.3390/pharmaceutics15030893]

[163] ClinicalTrials.gov. Lipid based Nanoparticles. Available from: https://clinicaltrials.gov/search?cond=cancer&term=Lipid%20based%20Nanoparticles. [accessed on 31 Jul 2024]